Avid Bioservices Inc (CDMO)

[biopharm]

Great post CJ with collaborators of Peregrine, now CDMO and wonder how many have continued ...

As for Dr Bernard Fox and his once ambition to use OX40, I wonder how convincing Dr Wolchok was in showing the better safety profile one can have with PS Targeting and I am sure more Biomarker discoveries would have been determined by comparison. Anyhow I am sure safety is #1 now ...knowing the FDA can use Biomarker data to prove that adverse events / patient deaths could be caused from OX40...or other off target toxicity causing drugs, where just a few years ago it would not raise a flag but Biomarkers are changing all that now.

"Other work by UbiVac and the firm’s collaborators has shown that a single dose of UbiVac’s DRibble cancer vaccine and anti-OX40 can significantly increase survival and provide apparent cure in about one third of animals bearing an advanced, difficult to treat, breast cancer. (NATURE Scientific Reports 22 November 2016) This and other research has motivated UbiVac to initiate a clinical trial combining both agents."

https://www.oregonbio.org/2017/10/13/portland-based-immuno-oncologist-dr-bernard-a-fox-to-present-at-siena-italy-conference/
http://www.ubivac.com

____

FROM PPHM’s 4-3-17 PR: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1019762

…”Latest Findings from Ongoing Collaboration with Memorial Sloan Kettering (MSK) Support Potential Applications for Combining CAR T & Anti-PS in Treatment of Solid Tumors”… For this study, a team of MSK researchers led by cancer immunotherapy thought-leaders, Taha Merghoub, Ph.D. and Jedd D. Wolchok, M.D., Ph.D., evaluated and compared the anti-tumor activity and off-target toxicities of adoptive T cell transfer therapy in combination with either PS-targeting antibodies or anti-OX40 antibodies in mice with advanced melanomas. Whereas PS-targeting and anti-OX40 demonstrated comparable tumor regression when administered in combination with transferred adoptive T cells, only the PS-targeting combination achieved these results without any off-target toxicities. By contrast, the anti-OX40 treatment combination triggered off-target inflammatory destruction of healthy tissues. Additional study results demonstrated that the PS-targeting antibodies decreased tumor-induced immunosuppression as evidenced by a decrease in immunosuppressive regulatory T cells (Tregs) and M2 macrophages. This finding is consistent with Peregrine’s belief that bavituximab may modulate the immunosuppressive tumor microenvironment and enhance the activity of immunotherapy agents.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130490016